The use of angiogenesis inhibitors in the complex treatment of neovascular glaucoma

Zotov, A.S.; Efremova, T.G.; Nesterova, Ekaterina; Solodkova, E.G.; Balalin, C.V.

doi:10.25276/2312-4911-2019-4-108-111

MTO

2019

DOI: 10.25276/2312-4911-2019-4-108-111

|View full text |Cite

The use of angiogenesis inhibitors in the complex treatment of neovascular glaucoma

A.S. Zotov¹,

T.G. Efremova²,

Ekaterina Nesterova³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Experience of Lucentis Application in Treatment of Neovascular Glaucoma Against the Background of Proliferative Diabetic Retinopathy

Zotov

Balalin

et al. 2021

Journal of Volgograd State Medical University

View full text Add to dashboard Cite

The study involved 23 patients (23 eyes) with neovascular glaucoma against the background of proliferative diabetic retinopathy. The first stage was the intravitreal injection of Lucentis, then with IOP > 25 mm Hg - transscleral cyclophotocoagulation and after 2 weeks panretinal laser coagulation in ischemic zones; with IOP < 25 mm Hg - panretinal laser coagulation in ischemic zones. At all observation periods there was a statistically significant decrease in IOP and in rubeosis. One week after the last stage of treatment the overall decrease in IOP was 33.4 % of the initial values, rubeosis was not detected. The application of Lucentis in combination with transscleral cyclophotocoagulation in the treatment of neovascular glaucoma against the background of proliferative diabetic retinopathy allows to achieve stable IOP normalization, preserving residual visual functions and reducing the risk of hemorrhagic complications.

show abstract

Experience of Lucentis Application in Treatment of Neovascular Glaucoma Against the Background of Proliferative Diabetic Retinopathy

Zotov

Balalin

et al. 2021

Journal of Volgograd State Medical University

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The use of angiogenesis inhibitors in the complex treatment of neovascular glaucoma

Cited by 1 publication

References 0 publications

Experience of Lucentis Application in Treatment of Neovascular Glaucoma Against the Background of Proliferative Diabetic Retinopathy

Experience of Lucentis Application in Treatment of Neovascular Glaucoma Against the Background of Proliferative Diabetic Retinopathy

Contact Info

Product

Resources

About